Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, Raja Prince-Eladnani, Ajay Nooka, David Vesole, Barry Paul, Parameswaran Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin Van Vliet, David Siegel, Saad Usmani, Frits van Rhee

Blood (2025) 146 (Supplement 1): 2220.

https://doi.org/10.1182/blood-2025-2220

Published: 2025

Journal Articles

Second primary malignancies in multiple myeloma: Incidence, survival and prognostic factors from a large single-center observational study

Blood (2025) 146 (Supplement 1): 2213.

https://doi.org/10.1182/blood-2025-2213

Published: 2025

Journal Articles

Low dose tocilizumab for mitigation of cytokine release syndrome with bispecific antibodies in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2210.

https://doi.org/10.1182/blood-2025-2210

Published: 2025

Journal Articles

Phylogenetic reconstruction reveals early divergence and late expansion of focal lesions in multiple myeloma

Blood (2025) 146 (Supplement 1): 685.

https://doi.org/10.1182/blood-2025-685

Published: 2025

Journal Articles

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2025-4598

Published: 2025

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes

Blood (2025) 146 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2025-4498

Published: 2025

Journal Articles

Functionally high-risk disease is associated with inferior outcomes after chimeric antigen receptor T-cell therapy for relapsed refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2291.

https://doi.org/10.1182/blood-2025-2291

Published: 2025

Journal Articles

Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study)

Blood (2025) 146 (Supplement 1): 2289.

https://doi.org/10.1182/blood-2025-2289

Published: 2025

Journal Articles

Surzetoclax (ABBV-453) in combination with daratumumab and dexamethasone in biomarker-selected patients with Relapsed/Refractory multiple myeloma: A Phase 1/2, multicenter, open-label platform study

Blood (2025) 146 (Supplement 1): 5844.

https://doi.org/10.1182/blood-2025-5844

Published: 2025

Journal Articles

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Blood (2025) 146 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2025-5840

Published: 2025

Journal Articles

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Blood (2025) 146 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2025-2237

Published: 2025

Journal Articles

Lenalidomide-related diarrhea is associated with gut microbiota dysbiosis and disruption of the bile acid pool

Blood (2025) 146 (Supplement 1): 2233.

https://doi.org/10.1182/blood-2025-2233

Published: 2025

Journal Articles

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

Sikander Ailawadhi, Divaya Bhutani, Antje Hoering, Adam Rosenthal, J Christine Ye, Prashant Kapoor, Saad Usmani, Manisha Bhutani, S. Vincent Rajkumar, Paul Gater, Robert Orlowski

Blood (2025) 146 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2025-1840

Published: 2025

Journal Articles

Final analysis of the evaluation of safety and efficacy of denosumab in patients with multiple myeloma and severe renal impairment: An IMWG bone subcommittee study

Evangelos Terpos, Ashraf Badros, Ioannis Ntanasis-Stathopoulos, Charalampia Kyriakou, Carlyn Tan, Niels Abildgaard, Michel Delforge, Dorotea Fantl, Cristina João, Emilie Carneiro, Saad Usmani

Blood (2025) 146 (Supplement 1): 1038.

https://doi.org/10.1182/blood-2025-1038

Published: 2025

Journal Articles

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Blood (2025) 146 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2025-1027

Published: 2025

Journal Articles

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 250.

https://doi.org/10.1182/blood-2025-250

Published: 2025

Journal Articles

Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

Tobias Tix, Mohammad Alhomoud, Jaromir Tomasik, Gloria Iacoboni, Edward Cliff, Doris Hansen, Saad Usmani, Gilles Salles, Marion Subklewe, Michael Von Bergwelt, Samuel Yamshon, Miguel-Angel Perales, Roni Shouval, David Cordas Dos Santos, Kai Rejeski

Blood (2025) 146 (Supplement 1): 8135.

https://doi.org/10.1182/blood-2025-8135

Published: 2025

Journal Articles

On the cellular origins of multiple myeloma

Blood (2025) 146 (Supplement 1): 5694.

https://doi.org/10.1182/blood-2025-5694

Published: 2025

Journal Articles

Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial

Blood (2025) 146 (Supplement 1): 2273.

https://doi.org/10.1182/blood-2025-2273

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Second primary malignancies in multiple myeloma: Incidence, survival and prognostic factors from a large single-center observational study

Low dose tocilizumab for mitigation of cytokine release syndrome with bispecific antibodies in relapsed/refractory multiple myeloma

Phylogenetic reconstruction reveals early divergence and late expansion of focal lesions in multiple myeloma

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes

Functionally high-risk disease is associated with inferior outcomes after chimeric antigen receptor T-cell therapy for relapsed refractory multiple myeloma

Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study)

Surzetoclax (ABBV-453) in combination with daratumumab and dexamethasone in biomarker-selected patients with Relapsed/Refractory multiple myeloma: A Phase 1/2, multicenter, open-label platform study

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Lenalidomide-related diarrhea is associated with gut microbiota dysbiosis and disruption of the bile acid pool

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom's macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL).

Final analysis of the evaluation of safety and efficacy of denosumab in patients with multiple myeloma and severe renal impairment: An IMWG bone subcommittee study

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

On the cellular origins of multiple myeloma

Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only